Abstract Number: PP08 • ACR Convergence 2025
Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…Abstract Number: 2296 • ACR Convergence 2025
Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study
Background/Purpose: Ianalumab, a glycoengineered, fully human, IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via a dual mechanism…Abstract Number: 1684 • ACR Convergence 2025
Integration of Multiple Spatial Transcriptomics Reveals Novel Insights into Sjogren Disease Salivary Gland Fibroblast by Peripheral Serostatus
Background/Purpose: Anti-SSA antibody positive (SSA+ [Ro52 or Ro60]) and negative (SSA-) Sjögren disease (SjD) have differing clinical phenotypes and prognostic features; however, the pathogenesis driving…Abstract Number: 1397 • ACR Convergence 2025
Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.
Background/Purpose: To evaluate the incidence of cardiovascular and cerebrovascular events (CVEs) in patients with Sjögren’s Disease (SjD), focusing on major adverse cardiovascular events (MACE), defined…Abstract Number: 1380 • ACR Convergence 2025
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…Abstract Number: 0515 • ACR Convergence 2025
Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
Background/Purpose: Oral and ocular dryness are hallmarks in patients with Sjögren’s disease (SjD). Given that activation of interferon (IFN) pathways has been shown to be…Abstract Number: 2665 • ACR Convergence 2025
Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
Background/Purpose: Ianalumab, an afucosylated mAb, depletes B cells via enhanced antibody (Ab)-dependent cellular cytotoxicity and blocks B cell-activating factor (BAFF): BAFF-receptor (BAFF-R) mediated signals.1 It…Abstract Number: 2295 • ACR Convergence 2025
Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI
Background/Purpose: To evaluate the clinical manifestations, systemic disease activity, and serological profile of patients of Primary Sjögren’s syndrome, and to assess associations between specific autoantibodies…Abstract Number: 1685 • ACR Convergence 2025
The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease
Background/Purpose: Performance of the recently developed composite responder index STAR is highly awaited. We conduscted this study to evaluate the performance of STAR in previously…Abstract Number: 1395 • ACR Convergence 2025
A Comparative Study of Yao Syndrome and Primary Sjögren’s Syndrome
Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly named Nucleotide-binding oligomerization domain containing protein 2 (NOD2)-associated autoinflammatory disease affecting multiorgan systems characterized by recurrent fever,…Abstract Number: 1378 • ACR Convergence 2025
Prevalence of Central Nervous System Manifestations in Sjögren’s Disease
Background/Purpose: Sjögren’s disease is a systemic autoimmune disorder with diverse clinical manifestations affecting multiple organ systems. While dry mouth, dry eyes, fatigue and pain are…Abstract Number: 0516 • ACR Convergence 2025
Association between anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies and lymphoma in primary Sjögren Disease (SD)
Background/Purpose: There is an unmet clinical need for identification of novel biomarkers of systemic complications and lymphoma in primary Sjögren disease (SD). Anti-cytosolic 5'-nucleotidase 1A…Abstract Number: 2499 • ACR Convergence 2025
Concomitant Anti-Ro/SSA Antibodies in Systemic Sclerosis Patients is Associated with Risks Beyond Dryness
Background/Purpose: Sjogren’s disease (SjD) is a common systemic autoimmune disorder characterized by progressive inflammation of the exocrine glands, resulting in dry eyes and dry mouth.…Abstract Number: 2294 • ACR Convergence 2025
Comparative Analysis of Patients Included in Trials Utilizing Biologic Drugs in the Treatment of Primary Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome is a heterogeneous autoimmune disease with no approved disease-modifying treatments. The aim of this systematic review was to evaluate primary Sjögren’s syndrome…Abstract Number: 1683 • ACR Convergence 2025
Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort
Background/Purpose: Sjögren disease (SD) is a B cell driven systemic auto-immune disease, with a need for biomarkers to better assess disease activity, risk of lymphoma…
- 1
- 2
- 3
- …
- 24
- Next Page »